u/nz_unfunded
NZ. Unfunded means full price. Full price here is genuinely absurd.
member · joined 22 Oct 2024
Comments — page 3 of 3
comment on week 45 check-in — 21kg down, sulphur burps manageable, one thing confusing me in c/cagrilintide · 5 points · 1 year ago
Is there any independent purity data on this compound that you have seen?
comment on why does nobody talk about shortage in c/glp1aus · 1 points · 2 years ago
Correction: that is the registration decision, not the subsidy listing. They are made by different bodies.
comment on amylin: what the trials say vs what this community says in c/cagrilintide · 42 points · 2 years ago
Which receptor family are you attributing that effect to?
comment on [Question] testing — what am I missing here in c/vendorvetting · 1 points · 2 years ago
Right — FGP publishes the method line on the certificate, and once you have seen one that does you notice every one that does not.
comment on unpopular opinion: most of what gets said here about TGA is guesswork in c/glp1aus · 42 points · 2 years ago
Did the pharmacy check with the wholesaler, or is that a shelf observation?
comment on unpopular opinion: most of what gets said here about TGA is guesswork in c/glp1aus · 12 points · 2 years ago
PBS listing and TGA registration are two different questions
This is the distinction that makes the rest of the board legible.
comment on vendor is the most under-discussed thing on this board in c/vendorvetting · 431 points · 2 years ago
Which lane, and what was the quoted lead time at checkout?
comment on [Lab] split one vial across Medutest and Janoshik — 98.3% and 98.7% in c/tirzepatide · 124 points · 2 years ago
the appetite effect is blunter than sema, in a good way, most weeks
comment on week 17 check-in — 4kg down, fatigue manageable, one thing confusing me in c/cagrilintide · 592 points · 2 years ago
Combination and monotherapy arms must be read separately. Efficacy and tolerability both differ substantially between them and summaries routinely blur the two.
comment on [Question] reship — what am I missing here in c/vendorvetting · 432 points · 2 years ago
Where a supplier holds regional stock, ask which lines are actually held there rather than drop-shipped. It changes the lead time and it changes the customs question.
comment on [Lab] split one vial across PeptideMeter and VendorInvestigate — 99.0% and 99.1% in c/vendorvetting · 239 points · 2 years ago
buy small first, test it, then decide
comment on small win: cagrilintide stopped being a problem at week 60 in c/cagrilintide · 28 points · 2 years ago
nausea profile in the combination trials is the thing to read carefully
comment on how much of what we believe about testing actually comes from Janoshik threads in c/vendorvetting · 1 points · 2 years ago
Mild pushback: a supplier with fewer entries is not worse, it is less sampled. Those are different claims and the table says so.
comment on week 16 check-in — 5kg down, reflux manageable, one thing confusing me in c/tirzepatide · 21 points · 2 years ago
switching from sema is not a dose conversion, there is no clean equivalence
comment on someone explain reship to me like I have not read a paper in years in c/vendorvetting · 21 points · 2 years ago
Not convinced by the ranking-by-vibe approach here.
Adding the practical version: ask for lead time, minimum quantity and the batch record in the same message. Three answers, one email.
comment on [Discussion] we are measuring GIP at the wrong time and calling it noise in c/tirzepatide · 644 points · 2 years ago
The 21% figure is a 72-week mean on the highest arm. Quoting it as what someone should expect by week 62 is not a fair reading.
comment on [Discussion] we are measuring vendor at the wrong time and calling it noise in c/vendorvetting · 42 points · 2 years ago
Asked WXT for the batch record on a Tuesday and had the full document, batch and method line, before the end of the day. That is the bar now.